Amyloid-fibril formation: Proposed mechanisms and relevance to conformational disease

European Journal of Biochemistry

Volumn 269, Issue 14, 2002, Pages 3362-3371

  Žerovnik, Eva ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Amyloid fibrils; Conformational disease; Domain swapping; Kinetics; Mechanism of fibrillogenesis

Indexed keywords

AMYLOID; OLIGOMER; POLYPEPTIDE; PROTEIN;

CELLULAR PARAMETERS; ENERGY; FIBER; IMMUNITY; KINETICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; REVIEW; STRUCTURE ANALYSIS;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; ANIMALS; HUMANS; KINETICS; MODELS, CHEMICAL; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; PRION DISEASES; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; SENILE PLAQUES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036377156     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1033.2002.03024.x     Document Type: Review

References (107)

1. Protein folding and human disease
2. Filamentous nerve cell inclusions in neurodegenerative diseases
3. Oligomerizaiton and fibril asssembly of the amyloid-β protein
4. Normal and abnormal biology of the β-amyloid precursor protein
5. Protein aggregation in Huntington's and Parkinson's disease: Implications for therapy
6. Targeting small Aβ oligomers: The solution to an Alzheimer's disease conundrum?
7. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease
8. Oxidative stress in Alzheimer's disease
9. Structure of sau protein and assembly into paired helical filamements
10. Gelsolin inhibits the fibrillization of amyloid β-protein, and also defibrillizes its preformed fibrils
11. Metabolic regulation of brain Aβ by neprilysin
12. Linking ubiquitin, parkin and synphilin-1
13. Synucleinopathies: A pathological and molecular review
14. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein
15. α-Synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases
16. Activated Fyn phosphorylates α-synuclein at tyrosine residue 125
17. Parkin ubiquitinates the α-synuclein-interacting protein, synphi-lin-1: Implications for Lewy-body formation in Parkinson disease
18. α-Synuclein in Lewy bodies
19. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
20. Protein misfolding and disease; protein refolding and therapy
21. Prions, peptides and protein misfolding
22. General introduction and brief history of the amyloid fibril
23. History of the amyloid fibril
24. Prions: Disease propagation and disease therapy by conformational transmission
25. Conversion of yeast phosphoglycerate kinase into amyloid-like structure
26. Formation of amyloid-like fibrils by self association of a partially unfolded fibronectin type III module
27. Amyloid fibril formation by an SH3 domain
28. Amyloid-like aggregates of a plant protein: A case of a sweet-tasting protein, monellin
29. Designing conditions for in vitro formation of amyloid protofilaments and fibrils
30. A domain-swapped RNase A dimer with implications for amyloid formation
31. Human stefin B readily forms amyloid fibrils in vitro
32. Amyloid fibrils from muscle myoglobin
33. Amyloid fibril formation by a helical cytochrome
34. Protein misfolding, evolution and disease
35. Amyloid fibrillogenesis: Themes and variations
36. Folding-related dimerization of human cystatin C
37. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid
38. Why are 'natively unfolded' proteins unstructured under physiologic conditions?
39. Evidence for a partially folded intermediate in α-synuclein fibril formation
40. Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis
41. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy
42. A de novo designed helix-turn-helix peptide forms nontoxic amyloid
43. The equilibrium intermediate of β-lactoglobulin with non-native α-helical structure
44. Non-native α-helical intermediate in the refolding of β-lactoglobulin, a predominantly β-sheet protein
45. Acceleration of the folding of hen lysozyme by trifluoroethanol
46. Differences in the effects of TFE on the folding pathways of human stefins A and B
47. Trifluoroethanol and colleagues: Cosolvents come of age. Recent studies with peptides and proteins
48. Acceleration of the folding of acylphosphatase by stabilisation of local secondary structure
49. A glimpse of a possible amyloidogenic intermediate of transthyretin
50. Structural mobility of the human prion protein probed by backbone hydrogen exchange
51. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry
52. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping
53. Crystal structure of the human prion protein reveals a mechanism for oligomerization
54. Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily
55. Polymorphic fibrillar assembly of human amylin
56. Analysis of amyloid-β assemblies using tapping mode atomic force microscopy under ambient conditions
57. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing
58. Alzheimer's amyloid fibrils: Structure and assembly
59. Solid-state nuclear magnetic resonance techniques for structural studies of amyloid fibrils
60. Mechanisms of amyloidogenesis
61. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
62. Partial unfolding as a precursor to amyloidosis: A discussion of the occurrence, role, and implications
63. Conformational changes and disease - Serpins, prions and Alzheimer's
64. PABMB lecture. Protein dynamics, folding and misfolding: From basic physical chemistry to human conformational diseases
65. Proteins can adopt totally different folded conformations
66. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
67. On the nucleation and growth of amyloid β-protein fibrils. Detection of nuclei and quantitation of rate constants
68. Assembly of A β amyloid protofibrils: An in vitro model for a possible early event in Alzheimer's disease
69. Hierarchical self-assembly of chiral rod-like molecules as a model for peptide β-sheet tapes, ribbons, fibrils, and fibers
70. Watching amyloid fibrils grow by time-lapse atomic force microscopy
71. In-situ atomic force microscopy study of β-amyloid fibrillization
72. Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates
73. Quantifying amyloid by congo red spectral shift assay
74. Quantification of β sheet amyloid fibril structures with thioflavin T
75. Is Congo red an amyloid-specific dye?
76. Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization
77. Uncharged thioflavin-T derivatives bind to amyloid-β protein with high affinity and readily enter the brain
78. Energy landscape theory for Alzheimer's amyloid-peptide fibril elongation
79. Nucleated conformational conversion and the replication of conformational information by a prion determinant
80. A mathematical model of the kinetics of β-amyloid fibril growth from the denatured state
81. Oligomer formation by 3D domain swapping: A model for protein assembly and misassembly
82. Accessing the global minimum conformation of stefin A dimer by annealing under partially denaturing conditions
83. Protein folding and three-dimensional domain swapping: A strained relationship?
84. Design of three-dimensional domain-swapped dimers and fibrous oligomers
85. Multistep nucleus formation and a separate subunit contribution of the amyloidgenesis of heat-denatured monellin
86. Proline-dependent oligomerization with arm exchange
87. Three-dimensional domain swapping in p13suc1 occurs in the unfolded state and is controlled by conserved proline residues
88. Proline isomerization and its catalysis in protein folding
89. Lower kinetic limit to protein thermal stability: A proposal regarding protein stability in vivo and its relation with misfolding diseases
90. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
91. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
92. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
93. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons
94. Route for prion neuroinvasion
95. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases
96. Binding of a chaperonin to the folding intermediates of lactate dehydrogenase
97. Cellular functions of molecular chaperones
98. Cellular functions of cytosolic E. coli chaperones
99. Hsp104, Hsp70, and Hsp40: A novel chaperone system that rescues previously aggregated proteins
100. Ubiquitin, cellular inclusions and their role in neurodegeneration
101. Heat shock proteins: Endogenous modulators of apoptotic cell death
102. Molecular chaperone targeting and regulation by BAG family proteins
103. Vaccine development for Alzheimer's disease: A shot of good news
104. Blocking prion conversion. Highlights
105. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
106. Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure
107. Evidence concerning rate-limiting steps in protein folding from the effects of trifluoroethanol